Member Info for TR64

I hold all my original TUI shares, and sold the RI.

Key issues that will come into play, that will shore up TUI sp.
TUI 15 Boeing Max 737 will be able to fly again from March, TUI operates the second biggest fleet of Boeing 737 max with 15, with 6 operating out of the UK.

The EU will have the final say on the date that TUI Boeing 737 max can fly, all are registered in Germany, even the 6 flying out of the UK.

TUI share price dropped from £12 when the second Boeing 737 max crashed, and Boeing were already under warning about flying the plane after the first 737 max crashed.

Most long term investors know the problems this caused TUI, who had to lease 15 additional aircraft and the costs.
TUI were payed compensation last year by Boeing and put the orders back for the other 25 Boeing Max 737 3 years.

It reasonable to look forward and give an extra premium to TUI SP of 20% upward movement in March/April , as the Boeing Max flys again and is 35% more fuel efficient than Boeing other 737, but Airbus Neo are better and will customers be allowed by TUI to know if they are flying on a 737 MAX.

Double the amount of shares in the market will effect the sp, the 25 holding by banks and German Gov is silent, and that allows the company to operate how it needs to.

This bail out and new shares is nothing like Rolls Royce, as rolls royce have no market to sell to for 60% of there business, and that wont change in the next 3 years.

Taverham.

The Rights issue is based on your holding as of January 7th and allocated on the 11th January , selling your ordinary shares to fund the purchase of the rights issue, should not effect the rights issue you held on January 7 and allocated in the UK on January 11th

Your broker, as made a serious error, if you have lost any of your rights issue,as that is ring fenced till January 19th to exercise by you, its only after that date you lose the rights issue not exercised.

I sold my rights issue share yesterday, at £2.42, and did so, becaue I could see the capital from them making more ££ is other shares like EZJ, over the next year..

Its up to each person to decide where they think capital invested is best, so I am no way indicating to anyone EZJ is a good investment, its all personal choice based on ones own risk assessment,

Best of luck

neverdone this.

The Rights issue was fully taken up and the major investors who hold 36% of the shares took the full allocation.

The German Government had already given 3 billion euros , before this latest loan with banks that results in the consortium of banks and government getting 25% of the rights issue, but they are silent investors.

TUI is as strong as ever and it will take till mid next year to reach its usual 27 million customers it served in 2019, so IMO, its going to be a year before the share price gets above £7.00, and 3 years plus before it pays a dividend again.

Good luck all

neverdone.

You can sell your Existing Ordinary shares,
The question is do you need to raise capital to pay for the Rights Issue shares? as you wish to keep them ?

You have till January 19 to exercise and pay for the Rights Issue shares .

the only rights issue shares you can purchase is what you have been allocated.

If you sell half the Rights Issue shares, you can do so now without paying for them and receive the Price offered by the market which is approx £2.52, you can at any time between now and January 19 buy back those Ex rights shares you sold, that is, if you can get a price.

The bottom line is, you can sell the rights issue now and get the price offered without paying for them .

I see the link is removed, but am unsure why. Have I violated some terms and conditions? If so , please accept my apologies.
Please bare in mind Curevac are EU Based and operate from Germany, as do Bayer. The 300 million doses sold by Curevac are all to the EU, and as the German Government put £400 million into Curevac a few years ago, Curevac are obliged to supply up to 25 million doses under a separate agreement, once the 300 million doses are supplied to the EU.

Link details below

German biotech CureVac shouldn’t be discounted from being a major COVID-19 vaccine player despite being at the tail end of the race to market.

This is according to Marianne De Backer, Bayer’s head of business development who would have helped pen its vaccine deal with CureVac, speaking at the annual J.P. Morgan healthcare conference today.

“The unmatched need is enormous; we will need between 12 (billion) and 14 billion doses to get a full handle on the pandemic,” she said in response to an investor panel Q&A session Wednesday about Bayer's deal with CureVac. “So, we believe that every single company that is active in this field should continue to put all the effort in to curb this pandemic.”
The pair teamed up earlier this month, with Bayer taking up the heavy lifting on the production side. CureVac is still testing its mRNA vaccine in trials but is some way back from rivals Pfizer and fellow German biotech BioNTech as well as Moderna, which have all seen emergency use authorizations across several countries over the past two months as well as impressive 95% efficacy rates in late-stage tests.

It started its phase 3 trial program at the very end of 2020, with early data revealed in November showing broadly positive results, although tolerability remained a concern. It still sees its 2021 target for bringing the CVnCoV vaccine to market as doable.

“As part of our strategy, we have been going out and forming relationships with innovators; CureVac was one of those and we think that using their technology of using mRNA, not just in vaccines but in other disease areas, is very, very promising," De Backer added.

With Bayer taking up the roll out on behalf of Curevac, it means all regulatory side is taken care of and distribution chains are in place , due to Bayer logistics and experience in the EU.
Glaxo did not enter into any deal to be part of distribution regulatory affairs, pharmacovigilance, medical information, supply-chain . GSK have already in place JV on 3 other Vaccines.

GSK deal with Curevac still earns GSK on all vaccines apart from the existing Curevac vaccine, it also earns GSK capital in the value of Curevac as a company market capital and 10% of all the companys profits

https://www.fiercebiotech.com/biotech/jpm-curevac-s-new-pharma-partner-bayer-says-its-covid-vaccine-not-just-also-ran

If I read the RI correctly and trading it would work as follows? Please feel free to correct the below ..I do not use II or AJBell, or 212

if the RI are trading at £2.58, and you add on 0.95p = to 1.07 Euros, you get £3.53 as the share price, if you sell the RI, receive approx £2.57 each.
That takes into account the 0.95p already deducted from the SP .
From janaury 19, you have to have exercised the RI Shares and paid for them.
Any sold before that date, can be sold providing you have the capital balance in an account as cash, and receive the trading price offered on the RI

Should read £13 million on AZN

UK Hedge funds shorted GSK and made £4.5 million in December,
The same hedge funds shorted AZN and made £13 billion .

Only shares purchased by January 7th qualified for the RI.
The new RI shares were issued on January 11th, and that is based on everything you held on January 7th at close of business

Cabitegravir is showing very good results and outcomes
https://www.who.int/news/item/09-11-2020-trial-results-reveal-that-long-acting-injectable-cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women

Have Bloomberg made a mistake on GSK lung cancer ? drug Zejula

GlaxoSmithKline Plc set an ambitious goal of more than doubling the number of blockbusters in its portfolio by 2026 as the British pharma giant moves to revive its product lineup.

Medicines including lung cancer drug Zejula and an antibody treatment against Covid-19 could achieve blockbuster status -- annual sales of more than $1 billion -- in the next five years, Hal Barron, Glaxo’s chief scientific officer, said at the annual JP Morgan Healthcare Conference on Tuesday, according to a copy of his remarks. Barron listed more than 10 products that could cross that threshold, adding to 10 blockbusters the company already has.

Glaxo believes those vaccines and medicines in the late-stage portfolio “could change medical practice,” Barron said in his presentation. “Successful development of these assets underpins our confidence in the accelerated performance we expect to see as we move through 2021 and beyond.”

Glaxo has lagged peers including U.K. rival AstraZeneca Plc and sought to rejuvenate its pipeline. In 2018, the company put its consumer-health arm into a joint venture with Pfizer Inc. as part of an effort to refocus on drug development and expand into lucrative fields such as oncology. The same year the company bought cancer-drug maker Tesaro Inc. for $5.1 billion, followed by a $4.2 billion collaboration with Germany’s Merck KGaA.

Other products that Glaxo hopes will reach blockbuster status include: HIV drug cabotegravir, a vaccine against respiratory syncytial virus for older adults, and a therapy for severe asthma.

The drugmaker is developing potential Covid vaccines with partners including Sanofi, Canada’s Medicago Inc. and China’s Sichuan Clover Biopharmaceuticals Inc, along with possible antibody treatments. The company’s candidate with Sanofi was dealt a setback last month, delaying advanced trials after it failed to produce a strong enough response in older people. That pushed its potential availability to the end of this year.

Depends on your broker, how many brokers run their own funds? Don't be surprised by by actions of platforms that allow electronic trading
In my experience it's not a myth.

The Pound as been as low as £1.14 to $1.00

ALL my GSK have a sell price logged at £20.50, it would be a decent exercise if all investors set a sell price at above £19.00, it does exert pressure and you can request that none of your holding is made available to shorting.

Kept the remaining holding of TUI, but I did sell down some @£5.15 in November.

Difficult decisions, but in my opinion , other company shares like EZJ will climb sooner than TUI.
Pre Pandemic, 27 million people took Holidays with TUI, and to get back to those numbers might take till Mid 2022.

TUI are very solid in comparison to other tour operators.
Suspect the RI could trade up around £2.90, but everyone as to make their own decision .

25 RI shares, for every 29 shares held.

Sold the rights issue off at £2.41 .
It will be interesting to see if the price moves up on the RI